Gleevec Maker Immune From Antitrust Liability, 1st Circuit Affirms

Mealey's (August 24, 2018, 11:41 AM EDT) -- BOSTON — Allegations by two putative classes that Novartis Pharmaceuticals Corp. fraudulently procured a patent for the leukemia drug Gleevec are not plausible, and the drug maker thus cannot be subject...
To view the full article, register now.